Member Info for Moneymunch

Any large buy would take time to fill, especially a huge one for 117,500,000, and then gets reported after close when the broker balances his book for all trades that day, sometimes it and take several days before it's reported depending on liquidity. Gl ;-)

RNS Number : 5779O

Tower Resources PLC

04 October 2023

Logo Description automatically generated

4 October 2023

Tower Resources plc

("Tower" or the "Company")

Share Issuance to Energy Exploration Capital Partners LLC

Tower Resources plc (AIM: TRP), the Africa-focused energy company, announces that Energy Exploration Capital Partners, LLC ("EECP" or the "Placee"), in accordance with the terms of the investment deed (the "Deed") announced to the market on 16 January 2023, has requested that the Company issue 317,601,462 ordinary shares of 0.001p each ("Placing Shares") to the Placee. The purchase price of 0.04p per share, set by mutual agreement given that the market price remains below the Floor Price set out in the Deed, for the settlement amount of US$153,846.15 including fees, was previously prepaid by the Placee.

Application for Admission:

Application has been made for the Placing Shares to be admitted to trading on AIM with admission expected to take place on or around 9 October 2023. The Placing Shares will rank pari passu in all respects with all existing ordinary shares in the Company.

Total Voting Rights:

Following Admission of the Placing Shares, the Company's enlarged issued share capital will comprise 8,761,582,484 ordinary shares with voting rights. There are no Shares currently held in treasury. This figure of 8,761,582,484 ordinary shares may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the Disclosure Guidance and Transparency Rules of the Financial Conduct Authority.

 Genflow could be on many radars, given how many leading scientists believe Sirt6 is so fundamental and tought to be the most potent and important gene for longevity, healthspan and multiple disease targets, and so every chance of a Major investor and or JV partner in the not too distant...in the meantime, there's plenty of material news to add significant value in the pipeline that could land at anytime. Gla :-)

All bodes well...Gla :-)

Perfectly poised!!! Gla :-)

Mon, 2 October 2023

Crypto's top CEOs are playing a pivotal role in driving funding for longevity research and anti-ageing technology, a leading scientist has claimed.

Longevity Escape Velocity Foundation president Aubrey de Grey, shared his insights in a recent episode of Yahoo Finance's The Crypto Mile.

De Grey highlighted the crypto community's support for both non-profit initiatives and investment ventures in the longevity sector.

He said that influential figures like Hex's Richard Heart, ethereum's (ETH-USD) Vitalik Buterin, Coinbase's (COIN) Brian Armstrong, and Cardano's Charles Hoskinson are engaged in both non-profit initiatives and investment ventures within the longevity sector.

"Brian Armstrong, co-founder of Coinbase, created a company called New Limited, which he put north of $50m in to, and Cardano's Charles Hoskinson has created an anti-ageing clinic in Wyoming," de Gray added.

The longevity scientist further noted that on the non-profit side of anti-ageing research, several donors from the cryptocurrency sector have contributed significantly.

"The biggest and most conspicuous example in that regard is the Hex community, the community of people who made their money out of the cryptocurrency called Hex, led by Richard Heart," said De Grey.

"Richard had this wonderful idea a few years ago to encourage his flock to donate to the SENS Research Foundation, and that worked out very well to the tune of $27m."

Investment from sovereign wealth funds and the private sector

According to a report, the longevity sector is experiencing increasing momentum and is projected to reach a market size of $44.2bn by 2030, with a compound annual growth rate (CAGR) of 6.1% from 2021 to 2030.

Capital inflow into the field has surged, with notable contributions from individuals like Amazon's Jeff Bezos and substantial investments from sovereign wealth funds, particularly from the Middle East and Asia. De Grey pointed out that this influx of funding began around 2017 when private sector involvement was minimal, but it has grown exponentially in recent years.

De Grey underscored how sovereign wealth funds, especially from the Middle East and the Far East, have started to get involved. Saudi Arabia's goal of investing $1bn annually, has created a ripple effect, inspiring other nations to follow suit.

Tower Resources PLC (AIM:TRP) told investors that it is “currently at a very advanced stage of negotiations” for a rig contract for the NJOM-3 well in Cameroon and expects it will be concluded soon.

“The rig contract is the critical next step in finalising the timing of the well, and so everything else depends on it and naturally follows it,” Tower chief executive Jeremy Asher said in the company’s interim results statement.

“The rig contract will still leave a wide operational tolerance for the well spud date, based on the timing of the current operations which the rig is undertaking, but it will be a firm commitment between the rig owner and the company.

“We are working with the Ministry of Mines, Industry and Technological Development on documenting the promised license extension to reflect the rig contract and especially the operational tolerances that it will contain.

“We expect the rig contract to be conditional on the formal documentation of the license extension, and although it is no longer feasible to spud the well in 2023, we are still hoping to be able to spud the well in the first half of 2024.”

In terms of the financial results, the pre-revenue exploration company had just shy of US$1 million of cash at the end of June and it is advancing a farm-out process in order to fund its share of costs for the NJOM-3 operations.

Asher added: “Our objective is still to farm out a minority share of the license interest, which should provide most or all of the remaining funding required for the well.

“The funding requirement was most recently estimated at US$13.4 million, though this estimate is always subject to change.

“We are discussing this with multiple parties, and one discussion is now at a very advanced stage.

“Any funding agreement will likely depend on the rig contract and the license extension documentation being completed.

“We are also still discussing credit facilities with the local Cameroon banks, although the difficulties of reconciling their requirements with a farm-out type of funding agreement have led us to prioritise the farm-out discussions over the bank discussions for the time being.”

We await the next UPdate from Cameroon, expected soon as intimated by JA in today's interview, the news from South Africa is excellent for imminent for TotalEnergies plans to develop and produce the two mega gas discoveries that straddle Tower's South Africa acerage...the greenlight will be highly significant for Tower. Gla :-)

South Africa’s Luiperd-Brulpadda Gas Fields Represent Huge Opportunities; We Must Not Let Them Pass Us By

27/6/23

By NJ Ayuk, Executive Chairman, African Energy Chamber

....

Potential Power Generation

For decades, oil and gas exploration in South Africa had yielded what our report describes as “scattered and sporadic success.”

But all of that changed in 2019 when Total (now TotalEnergies) announced its Brulpadda discovery, followed by the Luiperd discovery one year later. Brulpadda Field is estimated to hold at least 275 million barrels of oil equivalent (MMboe), and Luiperd’s estimated reserves are approximately 340 MMboe, with 70% gas each in both discoveries.

These numbers are huge and among the largest made in our continent in their respective years.

“Brulpadda accounted for 10% of the overall discovered volumes in Africa in 2019, and Luiperd accounted for a whopping 80% of the overall volumes discovered in 2020,” our report notes.

When the Brulpadda and Luiperd fields come online, their cumulative average output is estimated to be around 35,000 barrels per day of liquids and about 100,000 barrels of oil equivalent per day (boepd) of natural gas.

htTps://www.africa.com/south-africas-luiperd-brulpadda-gas-fields-represent-huge-opportunities-we-must-not-let-them-pass-us-by/

0  0 0

CAPE TOWN, Oct 2 (Reuters) - South Africa's environment ministry has given the go-ahead for TotalEnergies (TTEF.PA) to drill offshore for gas and oil, after rejecting an appeal from more than a dozen individuals and lobby groups who intend challenging the decision.

The appeal to stop TotalEnergies from drilling in Block 5/6/7 off the Cape coast was the latest in a series of actions seeking to halt energy companies exploring for new offshore discoveries at the foot of Africa.

TotalEnergies, which discovered two massive gas fields off South Africa in 2019 and 2020, did not immediately respond to a request for comment. Its area of interest in the block covers some 10,000 square km and is located roughly between Cape Town and Cape Agulhas, some 60 km from the coast at its closest point and 170 km at its furthest, in water depths between 700 metres and 3,200 metres.

TotalEnergies, the operator with a 40% stake, and partners Shell (SHEL.L), also with 40%, and national oil company PetroSA holding the remaining 20%, propose drilling up to five exploration wells in the block.

The last time the sp was at this low was 6 months ago, a Company Update was released followed by the Final Results which saw the stellar rise in sp from sub 2p to 5p plus, and so let's see what happens on the release of the Half Year Results expected end of this month, which no doubt will have substantial detail on proceedings, including the status of the planned Werner Syndrome, accelerated clinical trials and maybe a further UPdate on the two non-dilutive research grants mentioned by Eric in his interview, which will see Genflow fully cashed for 80% of their R&D well into 2026. Gla Holders. Gla Holders...Fill ya Boots at this rockbottom bargain low.....this will bounce big in the coming days imho.....On and eventually UP!!! ;-)

 Today's Rns was probably released because of Eric's disclosure in his interview with Proactive Investors on Monday, and looks like a bit of tree shake before the release of the Half Year Results expected end of next week, which will mo doubt have substantial detail on progress made, with every chance of confirmation of the two non-dilutive research grants mentioned by Eric in his interview, also news on the status of the planned accelerated Werner Syndrome clinical trials and maybe news on patents etc...News of a Major investor and or JV partner could also be in the pipeline...Genflow's current low offers tremendous near term upside...On and UP!!! :-)

Eric confirmed in his recent interview Genflow are in negotiation for two non-dilutive research grants which would provide funds for 80% of R & D for an additional 3 years, fully cashed well into 2026, and so confrmation news in the pipeline along with an update on their Werner Syndrome accelerated clinical plans. Gla Holders.....a Major investor or JV partner could pop UP at anytime. ;-)

..............................

The Company is headquartered in London and has a Belgian R&D subsidiary, Genflow Biosciences SRL (“Genflow BE”) that was established in 2020. Genflow BE’s location enables it to benefit from the relatively low operating costs and from substantial (non diluting) grants that support its research and development that are available from Belgium’s Wallonia region.

In addition to pre-clinical activities, Genflow seeks an earlier path to revenue with respect to Werner Syndrome, a rare progressive disorder characterised by the appearance of unusually accelerated ageing.

Genflow intends to conduct a European Phase I/II clinical trial with Werner Syndrome patients. The Company believes that positive clinical data will be the source of significant value creation through, potential acquisition or licensing arrangements. Moreover, a trial in Werner Syndrome will support the path to a specific aging indication.

RNS Number : 9615M

Genflow Biosciences PLC

20 September 2023

20 September 2023

Genflow Biosciences Plc

("Genflow" or "the Company")

Successful first regulatory interaction with the Federal Agency for Medicines and Health Products (FAHMP)

And

Internal Debt Restructuring

First regulatory agency interaction results in recommendation to commence Phase I/II Clinical Trial in NASH Patients

The Company (LSE:GNF) (OTCQB:GENFF), today announces the receipt of written comments from the Federal Agency for Medicines and Health Products (FAHMP) of Belgium. The Company is pleased with the advice received from the FAHMP to commence clinical trials of its drug, GF-1002, with patients suffering from NASH [*] (rather than in healthy volunteers). This follows promising results from the Company's research in in-vitro human cells and in-vivo rodent studies.

The Company's NASH clinical trials are scheduled to begin in approximately 18 months following dialogue and subsequent agreement with the European Medicine Agency.

Eric Leire, CEO of Genflow, commented; "We are thrilled that the FAHMP has recommended Genflow to commence Phase I/II clinical trials in NASH patients rather than with healthy volunteers. We hope that this will provide a first signal of efficacy in humans more speedily. We will continue to seek guidance and recommendations from the FAHMP to develop an appropriate program in conducting our proposed clinical trial in humans.

We are hopeful that these trials will showcase the ability of longevity gene-therapy assisting patients with life-limiting illnesses.

The current financial outlook for the Company remains positive as it is in a secure financial position. Genflow Biosciences has sufficient cash reserves until March 2025 and continues to seek further non-dilutive funding in the form of research grants."

Internal Debt Restructuring

In order to comply with the updated requirements of the existing grant from the Wallonia region, and to be eligible for future grant funding, Genflow recently undertook an internal debt re-organization.

This was completed by means of the benefit of the receipt of the existing loans between the Company and its ultimate subsidiary entity, Genflow Biosciences SRL ("Genflow BE"), being assigned to Genflow Biosciences, Inc ("Genflow US"), the Company's immediate subsidiary. This was then followed by a capital restructure within Genflow BE, resulting in an increase to this entity's net assets within the parameters and requirements of the possible grant providers. The overall debt position within the Group, therefore, remains unchanged.

Whilst this does not provide any assurances relating to the granting of non-dilutive funding in the Company's favor, it allows the Company to be considered for the same.

Full transcript from Eric's interview. Gla :-)

https://www.proactiveinvestors.com/companies/news/1026930/genflow-biosciences-ceo-reveals-the-secrets-of-longevity-an-exclusive-interview-with-dr-eric-leire-1026930.html?rel=scroll

Genflow is somewhat under the radar, and small cap Bio's along with many Aim listed stocks mostly require official Rns confirmation these days to get the sp moving, positive material news and funding, without dilution should do the trick, and usually best to get in on the low before any potential news that could add value is delivered imho. Gl :-)

A great interview with Eric, who confirms drtsils of Genflow's recent meeting with the European Health Agency will be announced soon and intimated that they have their full support along with the FDA. Also confirmed was their current 18 month cash runway but Eric stated they're in negotiations for two additional Funding Grants that would cover 80% of their R&D for an additional 3 years, fully cashed up until 2026. Very exciting stuff and looking forward to the Update/results. Gla :-)

Nice one Troajan. :-)

 A very exciting period ahead as we eagerly await the next UPdate/results on progress made, and given Sirt6 is believed to be fundamental and the most potent and important gene for longevity, healthspan and multiple disease targets, every chance of a Major investor and or JV partner wanting in early, which would be truly transformational for all concerned. Gla holders. :-)

The next Longevity Investors Conference will be held in Gstaad on September 27-29 2023

About Longevity Investors Conference (LIC)

The Longevity Investors Conference is bringing together the world's leading longevity key opinion leaders and scientists, institutional and private investors, wealthy private individuals, family offices, and investment funds. The main aim of the event is to discuss the latest trends and opportunities but also to provide relevant insights into the longevity and rejuvenation industry. As an investors-only conference, the event is fully focused on investors.

https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/fourth-longevity-investors-conference-held-130000286.html

Last chance to get in at this current lowly low, UPdate/ Results excepted this month which will add significant value imho!!! Gla holders...On and UP!!! :-)